Orthovita, Inc. Launches Vitoss(TM) Bioactive Foam-2X Bone Graft Substitute at AAOS (American Academy of Orthopedic Surgeons) Meeting

MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, confirmed today at the American Academy of Orthopedic Surgeons (AAOS) annual meeting in San Diego, California, that it is launching Vitoss Bioactive Foam-2X Bone Graft Substitute (“Vitoss BA2X”), a non-structural bone void filler for use in the pelvis, extremities and posterolateral spine.

Back to news